Latest Information Update: 19 Dec 2007
At a glance
- Originator Wyeth
- Class Antineoplastics
- Mechanism of Action Cytokine stimulants; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 25 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
- 15 May 2000 Phase-II clinical trials for Non-small cell lung cancer in USA (unspecified route)